Viatris Inc.
VTRS
Jodie situation report
Viatris Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 15 directly disclosed connections are confirming.
- Constant-currency net sales fell ~$6.6M (2%) vs prior year for existing products in Japan and Australia due to government price reductions and additional competition.
Invalidation: The isolated read changes if VTRS's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind VTRS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TBPHTheravance Biopharma, Inc.partnerFeb 26, 2026 ▾
“Theravance Biopharma The Company has a development and commercialization collaboration with Theravance Biopharma, for revefenacin.”
Depended on by
TBPHTheravance Biopharma, Inc.partnerMay 7, 2026 ▾
“The stability of revefenacin in both metered dose inhaler and dry powder inhaler (“MDI/DPI”) formulations suggests that revefenacin could also serve as a foundation for novel handheld combination products.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 17 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
VTRS is currently a Leader in the organic co-movement group Specialty & Generic Drugs. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for VTRS; it is not active in the latest market snapshot.